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Objectives. The aim of this study was to investigate the release
kinetics of endothelin after induced short-lasting myocardial
ischemia.
Background. Endothelin is an endothelium-derived vasoactive
peptide. Unequivocal proof of its cardiac release in ischemic
syndromes has not yet been demonstrated.
Methods. A coronary sinus study with atrial pacing was per-
formed in 23 patients with coronary artery disease. Endothelin
(ET), cardiac troponin-T (TnT), myoglobin (Mb) and creatine
kinase (CK) samples were withdrawn from the coronary sinus and
a peripheral vein before and 1, 5, 10, 30 and 45 min and 1, 2, 3 and
6 h after pacing. The appearance of angina pectoris, abnormal
cardiac lactate metabolism and ST segment depression were
further criteria for myocardial ischemia.
Results. In the study group, pacing stress induced severe
ischemia (mean duration 6 SD 6.1 6 1.2 min), with a maximum
of 0.34 6 0.12-mV ST segment depression in 21 of 23 patients and
angina pectoris in 22 of 23. The maximal cardiac lactate produc-
tion was 42.8 6 17.3% (p < 0.03). TnT and CK levels in the total
group were normal; in 14 of 23 patients a transient elevation of
Mb with a maximum after 3 h was detected (86.4 6 27.1 mg/liter,
p < 0.03). The ET concentrations increased significantly (p <
0.001) in the coronary sinus (from 4.6 6 0.8 [baseline] to 12.9 6
2.7 pg/ml at 1 min after cessation of pacing) and the peripheral
vein, respectively (from 4.7 6 0.7 [baseline] to 8.3 6 2.1 pg/ml at
1 min). ET further remained elevated for 1 h with persisting
higher coronary sinus than peripheral venous concentrations,
indicating cardiac ET release. In a control group of 18 patients
without heart disease, all variables were unchanged.
Conclusions. Short-lasting severe myocardial ischemia was
associated with significant ET release of cardiac origin that lasted
up to 1 h.
(J Am Coll Cardiol 1997;30:942–6)
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Endothelin (ET) is an endothelium-derived vasoactive media-
tor that was discovered in 1988 (1). Three isoforms of ET
(molecular weight 2,492 daltons) have been described, each
consisting of 21 amino acids and four cysteine residues that
form two disulfide bonds (1,2). ET has multiple biologic
actions, it contracts vascular and nonvascular smooth muscles
in vitro, produces a sustained and long-lasting pressor response
in vivo and exerts a positive inotropic effect on the cardiac
muscle (2–4). Increased plasma ET concentrations have been
reported in a variety of cardiovascular disorders. ET is sup-
posed to play a role in the pathophysiology of acute coronary
syndromes.
A possible role of ET in myocardial infarction is suggested
because circulating ET increases within hours after the onset
of infarction in humans (5–8). An ET increase in unstable
angina and transient myocardial ischemia is discussed contro-
versially (9–11); however, normal levels have varied almost
threefold from study to study, and this variation may reflect
differences in sampling site as well as variations in the speci-
ficity of the ET antibodies employed for radioimmunoassay
(RIA). ET achieves its highest concentrations at the site of its
release (1). The coronary endothelium as a source for ET
release after a myocardial ischemia has not yet been proved.
The aim of our study was to elucidate whether a brief
period of myocardial ischemia not leading to myocardial
infarction may increase plasma ET levels and to determine the
kinetics of a possible cardiac ET release.
Methods
Coronary sinus study. A coronary sinus lactate study with
incremental atrial pacing was performed in 23 patients (15
men, 8 women; mean age 6 SD 59.1 6 5.6 years) with
significant obstructive coronary artery disease and normal left
ventricular function. Significant stenosis was defined as $70%
diameter narrowing in an epicardial coronary artery. These
patients had not been able to reach the predicted submaximal
exercise level in the Bruce treadmill protocol because of
unspecified fatigue or dyspnea or because of intermittent
claudication in those with peripheral occlusive vascular dis-
ease. Exercise stress testing had also not been possible in four
patients with an artificial leg. In all patients, significant stenosis
was present in the ramus interventricularis anterior and in all
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other arteries classified as diseased. Seven patients presented
with a one-vessel disease, 14 with two-vessel disease and 2 with
three-vessel disease. The coronary sinus lactate study was
performed to demonstrate or to exclude myocardial ischemia
and to clarify the need for coronary revascularization.
The study was performed 1 day after the diagnostic cardiac
catheterization in patients with stable sinus rhythm. Standard
therapy consisted of aspirin (100 mg daily). No anti-ischemic
acting drugs were given 48 h before the study. Patients with
preexisting ST segment abnormalities—due, for example, to
left or right bundle branch block, left ventricular hypertrophy
or digitalis medication—were excluded from the study. At the
beginning of the study all patients were free of symptoms and
had no evidence of myocardial ischemia on a 12-lead electro-
cardiogram (ECG). A 7F Zucker catheter (USCI, Bard, Ire-
land) was positioned in the coronary sinus for incremental
atrial pacing and blood sampling. The tip of the catheter was
positioned ;2 to ;5 cm from the orifice of the coronary sinus
to minimize the risk of admixture of right atrial blood in the
samples. The correct position was confirmed by hand injection
of dye. Pacing was performed for 3 min each at 100, 120, 140
beats/min and (twice) at 160 beats/min. A 12-lead ECG was
obtained before pacing, after each 3-min pacing period and for
10 min at 1-min intervals after cessation of pacing.
Paired blood samples for creatine kinase (CK), cardiac
troponin-T (TnT), myoglobin (Mb) and ET were withdrawn
from the coronary sinus and an indwelling catheter in a vein of
the forearm before and at 1, 5, 10, 30 and 45 min and 1, 2, 3 and
6 h after pacing. At the same times and at the end of every
3-min pacing interval, paired samples for lactate were with-
drawn from the coronary sinus (cv) and an indwelling catheter
in the radial artery (a). By definition, negative values stand for
lactate extraction, positive values for lactate production. Myo-
cardial ischemia was defined as a reduction of cardiac lactate
extraction greater than 210% or a frank cardiac lactate
production .0%.
@a# 2 @cv# 3 @a#21 3 ~2100! 5 Cardiac lactate metabolism (%).
Pacing was stopped with the appearance of typical angina
pectoris. The duration of myocardial ischemia was quantified
by the persistence of angina and ST segment depressions in the
12-lead ECG after cessation of pacing (12).
Eighteen patients with angiographically normal coronary
arteries served as a control group (13 men, 5 women; mean age
60.7 6 4.9 years). All patients in the study and control groups
gave written informed consent; the study was approved by the
hospital ethics committee.
Laboratory analysis. The assays of all laboratory variables
were performed in blinded fashion without knowledge of
whether the patient from whom the sample had been obtained
was a member of the study group or of the control group.
Cardiac TnT. Cardiac TnT was determined by means of a
highly specific enzyme immunoassay (Boehringer Mannheim,
Germany). According to the manufacturer, the mean immu-
noreactive cardiac TnT concentration in healthy control sub-
jects is 0 to 0.5 mg/liter.
CK activity. CK activity was measured by an N-
acetylcysteine–activated, optimized ultraviolet test (Merck,
Darmstadt, Germany). The upper limits of the reference
interval of CK are 70 U/liter for women and 80 U/liter for men.
Mb. Mb concentrations were determined by a commer-
cially available immunoturbidimetric assay (Behringwerke AG,
Marburg, Germany). The upper limit of the reference interval
was 75 mg/liter, the sensitivity of the assay had a cutoff value
,50 mg/liter.
Plasma immunoreactive ET. ET samples were collected
into precooled EDTA–containing tubes (Sarstedt, Nu¨mbrecht,
Germany) and stored on ice. Samples were centrifuged at 2°C
for 20 min (2,000 3 g) within 30 min after collection and stored
at 270°C for ,7 days. Under these conditions no decrease in
measured plasma ET concentrations was observed.
Plasma ET concentration was measured by an RIA (Nich-
ols Institut Diagnostics B.V., Wijchen, Netherlands) as de-
scribed earlier (13). Preliminary purification of ET was per-
formed on silica C18 cartridges after acidification of plasma. A
competitive RIA was used with 125I-labeled tracer and a
polyclonal rabbit antibody. Bound and free hormones were
separated by a second antibody solid phase system followed by
centrifugation. The ET-1 antibody exhibited cross reactivities
of 52% with ET-2, 96% with ET-3 and 7% with big ET,
respectively, but no cross reaction with unrelated peptides such
as atrial natriuretic peptide, angiotensin-II, vasopressin or
adrenocorticotropin. The sensitivity of the assay was 1 pg/ml
and the intraassay and interassay coefficients of variation were
6.8% and 7.9%, respectively. According to the manufacturer,
the mean 6 SD ET concentration in healthy control subjects
(peripheral venous blood) is 4.0 6 0.67 pg/ml (range 2.54 to
5.29 pg/ml). Low and high concentration quality control sam-
ples were prepared by adding ET to EDTA plasma, stored in
aliquots at 270°C and assayed in each batch. Recovery of ET
was investigated by adding 5 pg/ml and 20 pg/ml ET-1 to
EDTA plasma from healthy control subjects. Recovery rate of
added ET was 96% and 98% for 5 and 20 pg/ml, respectively.
Statistical analysis. The means of the baseline data of the
Mb concentrations and cardiac lactate metabolism, respec-
tively, were compared with the means of their maximal in-
crease after pacing by a paired Student t test (p , 0.05 was
considered significant). The differences in values between the
ET concentrations in the coronary sinus and peripheral venous
blood before and at every sampling time after pacing were
assessed by an alpha-adjusted Bonferroni analysis (multiple
Abbreviations and Acronyms
CK 5 creatine kinase
CLM 5 cardiac lactate metabolism
ECG 5 electrocardiogram
ET 5 endothelin
Mb 5 myoglobin
RIA 5 radioimmunoassay
TnT 5 troponin-T
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comparison analysis) preceded by a two-way analysis of vari-
ance with repeated measures (p , 0.005 was considered
significant). A Pearson correlation analysis and a multiple
linear stepwise regression analysis were performed to investi-
gate the influence of the severity of myocardial ischemia
(lactate metabolism, ST segment depressions, duration of
angina pectoris) on the increase in ET (p , 0.05 was consid-
ered significant). Values are presented as mean value 6 SD.
Results
In the study group, pacing stress induced angina pectoris in
22 of 23 patients. The duration from the onset to the end of
angina corresponded well with the persistence of significant ST
segment depressions in the 12-lead ECG and cardiac lactate
production after the end of pacing (6.1 6 1.2 min). ST segment
depressions were documented in 21 of 23 patients (maximum
0.34 6 0.12 mV [range 0.2 to 0.6]) including the patient
without angina pectoris. ST depressions were flat in 12 of 21
patients, and downsloping in 9 of 21. Pacing was stopped
prematurely because of angina pectoris in 16 patients—at 120
beats/min in four, at 140 beats/min in two, at 160 beats/min
within the 1st 3-min interval in five and within the last 3 min of
the protocol in five.
Cardiac lactate production increased significantly from a
normal lactate extraction ,210% to a maximum of 42.8 6
17.3% (p , 0.03). Cardiac lactate metabolism (CLM) normal-
ized within 10 min after cessation of pacing in all patients. CK
and TnT remained unchanged in the total group. In 14 of 23
patients a transient and significant increase in Mb was docu-
mented (p , 0.03). The gradual increase in Mb in the latter
group was measured 2 and 3 h after the end of pacing; at 6 h
after the end of pacing, Mb had decreased to limits normal
levels. For the total study group, the Mb peak was 86.4 6 27.1
mg/liter (137.7% of the upper limit of normal). According to
World Health Organization criteria, no patient had had a
myocardial infarction. Nevertheless, pacing stress had induced
severe short-lasting myocardial ischemia (12,14).
The baseline concentrations of ET were 4.6 6 0.8 pg/ml in
the coronary sinus and 4.7 6 0.7 pg/ml in the peripheral vein.
A significant increase in ET was detected in the coronary sinus
as well as in the peripheral venous blood with an instantaneous
maximum after the end of pacing (p , 0.001) followed by a
gradual decrease to the limits of normal within 1 h. Peak ET
concentrations measured 1 min after the end of pacing were
12.9 6 2.7 pg/ml (243.9 6 51.0% of the upper limit of normal)
in the coronary sinus and 8.3 6 2.1 pg/ml (156.9 6 39.7% of
the upper limit of normal) in peripheral venous blood. The
concentrations continued to remain higher in the coronary
sinus than in the peripheral venous blood up to 2 h after the
cessation of pacing, indicating a persisting cardiac release of
ET (Table 1, Fig. 1). Significant differences in mean ET levels
were found in the coronary sinus between the baseline con-
centrations and the concentrations recorded 1, 5, 10 and
30 min after pacing, and in the peripheral venous blood
between the baseline levels and the concentrations recorded 1,
5 and 10 min after pacing (p , 0.001). (Preliminary data
reporting similar changes were published earlier [15]). There
was a tendency to higher ET levels in patients with more
accentuated myocardial ischemia (as measured by CLM, du-
ration of angina pectoris and degree of ST segment depres-
sions); however, the correlation was not significant by Pearson
analysis although multiple linear stepwise regression analysis
revealed a nearly significant partial correlation between the
increase in coronary sinus ET and both CLM (p 5 0.06) and
the duration of angina pectoris (p 5 0.07). In the control group
all variables were unchanged, and no myocardial ischemia or
ET increase was documented.
Discussion
Role of ET in cardiovascular disorders. The vascular en-
dothelium of coronary arteries releases vasodilator and vas-
constrictor agents that play an important role in the homeosta-
sis of coronary blood flow. The human endothelium produces
mainly ET-1, one of three isotypes (ET-1, ET-2, ET-3) discov-
ered in 1988 from the supernatant of endothelial cells in
culture (1). ET is the most potent vasoconstrictive peptide that
exerts a long-lasting pressure response on isolated coronary
arteries from animals (1) and humans (16). It produces a
marked increase in coronary vascular resistance in vivo (17).
Unlike other vasoactive peptides found in the coronary
circulation, ET is not stored in subcellular vesicles but is
dissolved in low concentrations in the cytoplasma. ET produc-
tion is enhanced by several stimuli that cause increased
transcription and translation of the pre-proendothelin gene
(18,19). In vitro studies have shown that ET secretion is
stimulated by vascular stretch and endothelial injury, shear
stress, sympathetic activation, thrombin, an impaired release of
endothelium-relaxing factor, endotoxin and hypoxia (20,21).
ET as a product of vascular endothelium likely achieves its
highest concentration and greatest action at the local vascular
site of its release (1,22). The ET concentrations decrease
Table 1. Cardiac Release Kinetics of Endothelin After
Myocardial Ischemia*
Coronary Venous Blood Peripheral Venous Blood
Baseline 4.6 6 0.8 (87.0 6 15.1%) 4.7 6 0.7 (88.8 6 13.2%)
After pacing
1 min 12.9 6 2.7 (243.9 6 51.0%) 8.3 6 2.1 (156.9 6 39.7%)
5 min 12.3 6 2.1 (232.5 6 37.8%) 7.9 6 1.7 (149.3 6 32.1%)
10 min 8.9 6 1.6 (166.3 6 30.2%) 6.4 6 1.0 (121.0 6 18.9%)
30 min 6.9 6 0.4 (130.4 6 7.6%) 5.9 6 1.1 (111.5 6 20.8%)
45 min 6.2 6 1.3 (117.2 6 24.6%) 5.1 6 0.9 (96.4 6 17.0%)
1 h 4.9 6 0.6 (92.6 6 11.3%) 4.6 6 0.8 (87.0 6 15.1%)
2 h 5.0 6 0.9 (94.5 6 17.0%) 4.8 6 0.3 (90.7 6 5.6%)
3 h 4.8 6 0.6 (90.7 6 11.3%) 5.1 6 0.6 (96.4 6 11.3%)
6 h 4.7 6 0.7 (88.8 6 13.2%) 4.9 6 0.5 (92.6 6 9.5%)
*Time course of plasma immunoreactive endothelin before (baseline) and
after pacing in the coronary venous and peripheral venous blood. Values shown
are mean 6 SD endothelin concentrations in pg/ml and, in parentheses, mean 6
SD percent of the upper limit of normal (5.29 pg/ml).
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rapidly because of biochemical breakdown or degradation
after reuptake by endothelial cells. ET is thought to play an
important role in cardiovascular regulation and pathophysiol-
ogy. A twofold to fivefold increase in immunoreactive ET
concentrations was reported in chronic heart failure and
cardiogenic shock (23–26). Release of ET was also found in
patients with hypertension and chronic renal failure (27).
ET in myocardial infarction and ischemia. It has been
suggested that ET might contribute to myocardial ischemia
and infarction. In several studies (8,25,28–30) elevated ET
concentrations of 2 to 10 times normal levels were found in the
early hours after myocardial infarction. ET concentrations
were markedly higher in complicated infarctions reflecting
depressed myocardial performance and recurrent myocardial
ischemia (28). In the rat heart an endothelin antibody reduced
experimentally induced infarct size (31).
In the study of Lechleitner et al. (29), no close correlation
was found between peak ET levels and the markers of myo-
cardial injury, suggesting that the stimulus of ET release is not
myocardial necrosis itself. This observation supports the hy-
pothesis that ET as a marker of endothelial perturbation is
determined by the severity of myocardial ischemia. Thus, a
possible association of ET with a transient myocardial ischemia
was proposed, although the contribution of ET to the patho-
physiology of unstable angina and myocardial ischemia is not
yet well understood. Hypoxia in acute coronary syndromes is
associated with a cascade of interactions between the athero-
sclerotic plaque, the endothelium and its local mediator sub-
stances, circulating platelets and coagulation factors (32).
Measurement of ET in induced ischemia in our study may
help to elucidate whether the increase of ET is an indication of
cell necrosis or is in some way related to the pathophysiology
of acute coronary syndromes. The diagnostic procedures of
cardiac catheterization and dye exposure do not modify ET
concentrations in plasma (33,34). The baseline concentrations
of ET in our study and control groups were similar and within
the manufacturer’s normal range (2.54 to 5.29 pg/ml) and
similar to levels found in other studies (28,29) using the Nicols
RIA. The laboratory markers of myocardial cell damage and
the ECG showed no evidence of myocardial necrosis in our
study. Exercise induced short-lasting frank cardiac lactate
production, significant ST segment depressions and a transient
increase of Mb characterizing severe myocardial ischemia in
our study group. Myocardial ischemia was followed by or was
associated with significant cardiac ET release. Owing to the
small number of patients in our study group, statistical analyses
failed to demonstrate a significant correlation between the
severity of myocardial ischemia and ET increase. However, the
multiple linear regression analysis data suggest that the results
might have become significant in a larger study group.
The ET elevation persisted for 1 h with higher levels in the
coronary sinus than in peripheral venous blood, despite the
short half-life of ET. This finding suggests that the release of
ET is an ongoing active process of cardiac origin. Our study
allows a detailed description of the time course of cardiac ET
release after well defined myocardial ischemia (Fig. 1). ET is
released locally in the coronary endothelium. Our data also
indicate that ET release may have a profound effect on
coronary vascular tone due to elevated coronary levels, despite
subthreshold concentrations in peripheral venous blood (Fig.
1; 45 min after cessation of pacing).
Conflicting results concerning ET release in unstable an-
gina were reported in other studies, probably because of early
sampling or interindividual variability of measurements. Ray et
al. (25) did not find increased peripheral venous ET concen-
trations in patients after rest angina pectoris with significant
ECG changes. In their study, blood samples were withdrawn
only once within a 4-h period after the onset of chest pain, and
the severity and duration of myocardial ischemia were not
quantified in detail. It is possible that their patients had only
mild chest pain and that the time of blood sampling was too
late to detect an ET increase. Similarly, Stewart et al. (9) did
not detect an ET increase in coronary venous blood in patients
with unstable angina. However, at the time of blood sampling
(4 to 24 h after an episode of chest pain with significant ECG
changes), their patients had been free of symptoms and the
Figure 1. Time course of plasma immunoreactive ET
release in the coronary venous (cv-ET) and peripheral
venous blood (pv-ET) and time course of the release of
CK (CPK), cardiac TnT and Mb in peripheral venous
blood depicted as percent of the upper limits of normal
on the left ordinate. The upper limits of normal are
5.29 pg/ml for ET, 70 U/liter (women) and 80 U/liter
(men) for CK, 0.05 mg/liter, for cardiac TnT and
75 mg/liter for Mb. The rate of CLM is shown in percent
on the right ordinate. The time of blood sampling ap-
pears on the abscissa: baseline [BL] and every 3 min
during incremental pacing at 100, 120, 140 and (twice)
160 beats/min (bpm); 1, 5, 10, 30 and 45 min; and 1, 2, 3
and 6 h after cessation of pacing. The onset and end of
angina pectoris (AP) are marked by arrows.
945JACC Vol. 30, No. 4 KRU¨GER ET AL.
October 1997:942–6 ENDOTHELIN RELEASE AFTER MYOCARDIAL ISCHEMIA
ECG had normalized. Although the data in these two studies
apparently contradict our findings, the most likely explanation
for the observed lack of ET increase is the delay of several
hours between the onset of chest pain and ECG changes and
the collection of blood samples.
In accordance with our data, Qui et al. (30) reported a
significant, 1.5-fold increase in peripheral venous ET concen-
trations in patients with persisting angina pectoris in whom
myocardial infarction had been ruled out. ET elevation was
also measured in the coronary sinus of patients with coronary
spastic angina associated with transient myocardial ischemia
(35). Our results strongly support the cardiac endothelium as
the source of ET release associated with or induced by
short-lasting severe myocardial ischemia. Our study documents
for the first time in detail unequivocal cardiac ET release
kinetics and it provides a plausible explanation for the appar-
ently conflicting results of earlier studies.
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